Atopic Dermatitis

Delgocitinib ointment was associated with improved efficacy over placebo in pediatric patients with moderate atopic dermatitis through 56 weeks of follow-up, according to a study.

Significant improvements were seen in atopic dermatitis symptoms in patients treated with an anti-OX40 monoclonal antibody, as well as continued improvement after discontinuation, according to phase 2 trial results.

An extension study found atopic dermatitis patients continuously treated with tralokinumab had long-term improvement in severity and those with interrupted treatment matched improvement after 12 weeks.

Although there is a link between allergic disease and mental health, this relationship does not appear to be causal, according to a study published in Clinical & Experimental Allergy.

Weekly dupilumab showed long-term safety and efficacy in atopic dermatitis patients in an open-label extension study presented at the EADV Congress virtual meeting.

Patients with mild to severe atopic dermatitis may benefit from long-term upadacitinib and topical corticosteroid treatment without any new safety risks, according to a study published in The Journal of Allergy and Clinical Immunology.

The FDA has approved Opzelura cream for the treatment of atopic dermatitis in non-immunocompromised patients, Incyte announced in a press release.

Health care workers with atopic dermatitis had greater irritation, dryness and other skin issues due to how frequently they washed their hands, according to a study published in Annals of Allergy, Asthma & Immunology.

A phase 3 trial of tapinarof cream for the treatment of atopic dermatitis has dosed its first patient, Dermavant Sciences announced in a press release.

Pediatric patients with atopic dermatitis who were treated with Dupixent plus topical corticosteroids had significant reductions in itch and improved quality of life in a phase 3 trial, according to a press release.